CAR-T, mosunetuzumab, and polatuzumab for hard-to-treat lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This Phase 2 trial tests a combination approach to treat certain aggressive, relapsed, or refractory non-Hodgkin lymphomas. It may help by using CAR-T cells (a patient-specific immune treatment) along with other lymphoma medicines to shrink or control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have one of these adult lymphomas: DLBCL, primary mediastinal B-cell lymphoma, transformed follicular lymphoma, high-grade B-cell lymphoma, mantle cell lymphoma, or Burkitt lymphoma.
- Your lymphoma must be “refractory” or have come back after specific past treatments (including certain chemotherapy plans).
- At least one tumor area must be measurable by scan (minimum size based on where it is).
- Your lymphoma cells must be CD19-positive (and a new biopsy may be needed if you had CD19-targeted therapy before).
- You must be able to do daily activities at a level of 0–2 on the ECOG scale, and be older than 18 years.
- Your organs must work well enough for treatment (kidney, liver, heart function, oxygen level, and blood counts must meet limits).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 study tests an anti-CD19 CAR-T cell treatment in adults with specific types of relapsed or treatment-resistant non-Hodgkin lymphoma. It may help by finding and attacking lymphoma cells that carry the CD19 marker, but it’s early-stage and eligibility is strict.
This Phase 2 study looks at giving CAR-T cell therapy first, then follow-up “bispecific” antibody medicines to help keep large B-cell lymphoma from coming back. It’s for people whose lymphoma returned or did not respond to prior standard treatments and who still have measurable disease on scans.
This trial tests a CAR-T cell treatment made to target CD19 on lymphoma cells (PL001). It’s for people whose B-cell lymphoma has come back or not responded to standard treatments, aiming to shrink the cancer and help control the disease.
This trial tests a special cell therapy called CAR-T that targets CD19 on lymphoma cells. It is for people with aggressive large B-cell lymphoma that has not responded to standard treatments or has come back after treatment.
This trial tests a new CAR-T treatment that targets three proteins on lymphoma cells (CD19, CD22, and BCMA). It is for people with certain types of B-cell lymphoma that have come back or are not responding to standard treatments.
This trial tests a combination treatment: a stem cell transplant followed by CAR-T cell therapy for people with B-cell lymphoma that has come back or not responded to treatment. It is for those with high-risk features like large tumors or certain genetic changes.
Hear when a new Refractory Non-Hodgkin Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.